Cantor Fitzgerald Estimates HRMY FY2025 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Harmony Biosciences in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the company will post earnings of $3.71 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $58.00 target price on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

Several other brokerages have also commented on HRMY. Needham & Company LLC restated a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a research report on Monday, January 13th. Oppenheimer restated an “outperform” rating and set a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Raymond James reiterated an “outperform” rating and set a $40.00 price target on shares of Harmony Biosciences in a research report on Thursday, October 10th. Mizuho upped their price target on Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Harmony Biosciences in a report on Thursday, January 16th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences presently has an average rating of “Buy” and an average target price of $55.00.

Harmony Biosciences Trading Down 1.7 %

Shares of HRMY stock opened at $38.01 on Wednesday. The business’s fifty day moving average price is $34.66 and its 200 day moving average price is $35.05. The firm has a market capitalization of $2.17 billion, a PE ratio of 18.01, a P/E/G ratio of 0.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. Harmony Biosciences has a 1-year low of $28.14 and a 1-year high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.15. The company had revenue of $186.00 million for the quarter, compared to analysts’ expectations of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm’s quarterly revenue was up 16.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.63 EPS.

Insider Buying and Selling

In other news, insider Jeffrey Dierks sold 10,507 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total value of $388,864.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jeffrey M. Dayno sold 19,293 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total transaction of $774,228.09. The disclosure for this sale can be found here. Insiders sold 77,419 shares of company stock worth $3,082,455 in the last ninety days. Insiders own 30.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Pacer Advisors Inc. grew its position in shares of Harmony Biosciences by 18.2% in the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock valued at $78,452,000 after purchasing an additional 351,582 shares during the period. KBC Group NV grew its holdings in Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock valued at $63,000 after buying an additional 819 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of Harmony Biosciences by 9.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 17,445 shares of the company’s stock valued at $600,000 after acquiring an additional 1,550 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Harmony Biosciences by 43.1% during the 4th quarter. SG Americas Securities LLC now owns 22,498 shares of the company’s stock worth $774,000 after acquiring an additional 6,774 shares during the period. Finally, ARS Investment Partners LLC acquired a new stake in shares of Harmony Biosciences in the fourth quarter worth approximately $841,000. 86.23% of the stock is currently owned by institutional investors and hedge funds.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.